FDA-cleared profile

Butterfly iQ/iQ+ Ultrasound System

Butterfly Network, Inc. · Ultrasound · FDA-cleared (510(k))

Authorized purpose: Butterfly iQ and iQ+ are handheld general-purpose ultrasound systems for adult and pediatric imaging; K220068 adds lung imaging, spectral pulsed-wave Doppler, and an Auto B-line Counter that identifies and counts B-lines for clinician review without diagnosing a specific pathology.

Clinical role
Portable ultrasound acquisition and measurement with an optional reviewed B-line overlay and count during lung scanning.
Images and patients
Ultrasound · Multi-region
Key limitation
Keep in mind: The overlay of B-lines does not mark images for detection of specific pathologies.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Butterfly iQ and iQ+ are handheld general-purpose ultrasound systems for adult and pediatric imaging; K220068 adds lung imaging, spectral pulsed-wave Doppler, and an Auto B-line Counter that identifies and counts B-lines for clinician review without diagnosing a specific pathology.
  • Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Multi-region Input: Live ultrasound data from the Butterfly transducer connected to a compatible commercial mobile device.
  • Who uses it?Intended users: Trained healthcare professionals providing diagnostic ultrasound.
  • What does the software produce?Output: The purpose of the Auto B-line Counter is to provide automated detection and automatic calculation of the number of B-lines to a user in a given rib space and also provides the user the capabilities of reviewing the detected B-lines (via visual overlays). The Butterfly iQ/Butterfly iQ+ Ultrasound System is indicated for use by a trained healthcare professional in an environment where healthcare is provided to enable diagnostic ultrasound imaging and measurement of anatomical structures and fluids of adult and pediatric patients for the following clinical applications: Peripheral Vessel (including carotid, deep vein thrombosis and arterial studies), Small Organs (including thyroid, scrotum and breast), Cardiac, Abdominal, Lung, Procedural Guidance, Urology, Fetal/Obstetric, Gynecological, Musculoskeletal (conventional), Musculoskeletal (superficial) and Ophthalmic. Modes of operation include B-mode, B-mode + M-mode, B-mode + Color Doppler, B-mode + Power Doppler, Spectral Pulsed Wave Doppler.
  • What is its most important limitation?Key limitation: The overlay of B-lines does not mark images for detection of specific pathologies.

Clinical takeaway. Clinical role: Butterfly iQ and iQ+ are handheld general-purpose ultrasound systems for adult and pediatric imaging; K220068 adds lung imaging, spectral pulsed-wave Doppler, and an Auto B-line Counter that identifies and counts B-lines for clinician review without diagnosing a specific pathology.

Evidence takeaway. Evidence from the reviewed source record: K220068 reports analytical validation on 6,000 deidentified cines from 253 sites and clinical performance evaluation in 99 subjects. The Auto B-line Counter was noninferior to clinician ground truth and consistent across age, sex, and body-mass-index subgroups, but no public numerical ICC is reported in the summary.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Butterfly iQ and iQ+ are handheld general-purpose ultrasound systems for adult and pediatric imaging; K220068 adds lung imaging, spectral pulsed-wave Doppler, and an Auto B-line Counter that identifies and counts B-lines for clinician review without diagnosing a specific pathology.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Portable ultrasound acquisition and measurement with an optional reviewed B-line overlay and count during lung scanning.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
Live ultrasound data from the Butterfly transducer connected to a compatible commercial mobile device.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Output and clinician action
The purpose of the Auto B-line Counter is to provide automated detection and automatic calculation of the number of B-lines to a user in a given rib space and also provides the user the capabilities of reviewing the detected B-lines (via visual overlays). The Butterfly iQ/Butterfly iQ+ Ultrasound System is indicated for use by a trained healthcare professional in an environment where healthcare is provided to enable diagnostic ultrasound imaging and measurement of anatomical structures and fluids of adult and pediatric patients for the following clinical applications: Peripheral Vessel (including carotid, deep vein thrombosis and arterial studies), Small Organs (including thyroid, scrotum and breast), Cardiac, Abdominal, Lung, Procedural Guidance, Urology, Fetal/Obstetric, Gynecological, Musculoskeletal (conventional), Musculoskeletal (superficial) and Ophthalmic. Modes of operation include B-mode, B-mode + M-mode, B-mode + Color Doppler, B-mode + Power Doppler, Spectral Pulsed Wave Doppler.
  • Exact FDA submission
  • Checked 2026-09-19

The exact packet supports imaging, measurement, the listed modes, and B-line detection/overlay; it does not state stored studies as an output.

Care setting
Clinical environments where healthcare is provided, including bedside, clinic, hospital, and other supported point-of-care settings.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Trained healthcare professionals providing diagnostic ultrasound.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Limitations
The overlay of B-lines does not mark images for detection of specific pathologies.
  • Exact FDA submission
  • Checked 2026-09-19

This is the packet's direct limitation for the Auto B-line Counter. The added interpretation, platform, integration, and security wording is not in the packet.

Evidence summary
K220068 reports analytical validation on 6,000 deidentified cines from 253 sites and clinical performance evaluation in 99 subjects. The Auto B-line Counter was noninferior to clinician ground truth and consistent across age, sex, and body-mass-index subgroups, but no public numerical ICC is reported in the summary.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K220068 reports analytical validation on 6,000 deidentified cines from 253 sites and clinical performance evaluation in 99 subjects. The Auto B-line Counter was noninferior to clinician ground truth and consistent across age, sex, and body-mass-index subgroups, but no public numerical ICC is reported in the summary.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or quantitative-biomarker function. Use the task-specific endpoints and tested population reported below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or quantitative-biomarker function. Use the task-specific endpoints and tested population reported below.

Analytical validation cines

6000 cines

  • EndpointB-line count and segmentation validation
  • PopulationButterfly iQ/iQ+ Ultrasound System
  • Tested versionButterfly iQ/iQ+ with Auto B-line Counter cleared in K220068

Collection sites

253 sites

  • EndpointAnalytical validation dataset
  • PopulationButterfly iQ/iQ+ Ultrasound System
  • Tested versionButterfly iQ/iQ+ with Auto B-line Counter cleared in K220068

Clinical evaluation subjects

99 subjects

  • EndpointNoninferiority to clinician ground truth
  • PopulationButterfly iQ/iQ+ Ultrasound System
  • Tested versionButterfly iQ/iQ+ with Auto B-line Counter cleared in K220068

K220068 FDA performance package for Butterfly iQ/iQ+ Ultrasound System

  • DesignManufacturer multisite analytical validation and pivotal clinical noninferiority evaluation against expert B-line annotations
  • PopulationAdults aged 20-90 with diverse demographic and clinical characteristics
  • Scopeexact submission
  • Tested versionButterfly iQ/iQ+ with Auto B-line Counter cleared in K220068
  • Samplen=99
  • Sites253
  • IndependenceSponsor or vendor study

K220068

Manufacturer evidence submitted for substantial equivalence; local clinical, technical, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K220068 by exact submission identifier.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

A zero-result exact-identifier search does not prove that no recall, correction, adverse-event report, or product-family safety signal exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the device within the applicable imaging or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Live ultrasound data from the Butterfly transducer connected to a compatible commercial mobile device.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K220068: Butterfly iQ/iQ+ Ultrasound System

  2. Routing

    Source context, not route validation: Mobile application and transducer workflow with product-family PACS or EMR connectivity; validate supported mobile operating systems, DICOM routing, patient matching, offline behavior, archive completeness, and fleet management.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA K220068: Butterfly iQ/iQ+ Ultrasound System · Butterfly iQ+ handheld ultrasound system · Butterfly iQ+ specifications and security information

  3. AI processing

    Source context, not route validation: Handheld transducer plus compatible iOS or Android device and licensed mobile or cloud services; map the exact transducer, app, operating system, and subscription to the cleared release.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA K220068: Butterfly iQ/iQ+ Ultrasound System · Butterfly iQ+ handheld ultrasound system · Butterfly iQ+ specifications and security information

  4. Returned objects

    Source context, not route validation: The purpose of the Auto B-line Counter is to provide automated detection and automatic calculation of the number of B-lines to a user in a given rib space and also provides the user the capabilities of reviewing the detected B-lines (via visual overlays). The Butterfly iQ/Butterfly iQ+ Ultrasound System is indicated for use by a trained healthcare professional in an environment where healthcare is provided to enable diagnostic ultrasound imaging and measurement of anatomical structures and fluids of adult and pediatric patients for the following clinical applications: Peripheral Vessel (including carotid, deep vein thrombosis and arterial studies), Small Organs (including thyroid, scrotum and breast), Cardiac, Abdominal, Lung, Procedural Guidance, Urology, Fetal/Obstetric, Gynecological, Musculoskeletal (conventional), Musculoskeletal (superficial) and Ophthalmic. Modes of operation include B-mode, B-mode + M-mode, B-mode + Color Doppler, B-mode + Power Doppler, Spectral Pulsed Wave Doppler.

    Scope: Exact FDA submission. The exact packet supports imaging, measurement, the listed modes, and B-line detection/overlay; it does not state stored studies as an output.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K220068: Butterfly iQ/iQ+ Ultrasound System

  5. Viewer/worklist/report

    Unresolved route: The purpose of the Auto B-line Counter is to provide automated detection and automatic calculation of the number of B-lines to a user in a given rib space and also provides the user the capabilities of reviewing the detected B-lines (via visual overlays). The Butterfly iQ/Butterfly iQ+ Ultrasound System is indicated for use by a trained healthcare professional in an environment where healthcare is provided to enable diagnostic ultrasound imaging and measurement of anatomical structures and fluids of adult and pediatric patients for the following clinical applications: Peripheral Vessel (including carotid, deep vein thrombosis and arterial studies), Small Organs (including thyroid, scrotum and breast), Cardiac, Abdominal, Lung, Procedural Guidance, Urology, Fetal/Obstetric, Gynecological, Musculoskeletal (conventional), Musculoskeletal (superficial) and Ophthalmic. Modes of operation include B-mode, B-mode + M-mode, B-mode + Color Doppler, B-mode + Power Doppler, Spectral Pulsed Wave Doppler.

    Scope: Exact FDA submission. The exact packet supports imaging, measurement, the listed modes, and B-line detection/overlay; it does not state stored studies as an output.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K220068: Butterfly iQ/iQ+ Ultrasound System

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Handheld transducer plus compatible iOS or Android device and licensed mobile or cloud services; map the exact transducer, app, operating system, and subscription to the cleared release.
  • Exact FDA submission
  • Checked 2026-09-03
Integration
Mobile application and transducer workflow with product-family PACS or EMR connectivity; validate supported mobile operating systems, DICOM routing, patient matching, offline behavior, archive completeness, and fleet management.
  • Exact FDA submission
  • Checked 2026-09-03
Security
Current iQ+ materials describe encrypted storage and TLS in transit for the product family. Confirm these controls, mobile-device management, identity, audit, retention, support access, vulnerability handling, and data residency for the exact contracted K220068 architecture.
  • Product family
  • Checked 2026-09-03

Confirm the controls against the exact contracted architecture and release.

Training
Only trained healthcare professionals providing diagnostic ultrasound. should operate or interpret the system. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: The B-line overlay does not diagnose a specific pathology. Users must interpret it with the examination and other clinical data; current iQ+ platform, integration, and security claims may not apply to every K220068 configuration.
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, and outputs to K220068 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Mobile application and transducer workflow with product-family PACS or EMR connectivity; validate supported mobile operating systems, DICOM routing, patient matching, offline behavior, archive completeness, and fleet management.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The B-line overlay does not diagnose a specific pathology. Users must interpret it with the examination and other clinical data; current iQ+ platform, integration, and security claims may not apply to every K220068 configuration.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

Vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: The B-line overlay does not diagnose a specific pathology. Users must interpret it with the examination and other clinical data; current iQ+ platform, integration, and security claims may not apply to every K220068 configuration.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K220068
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Ultrasound
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-03-31
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
11Source classes checked
20Screened PubMed leads
10Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, vendor product page, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

8 sources - 3 history items

Source ledger

  1. FDA K220068: Butterfly iQ/iQ+ Ultrasound System

    U.S. Food and Drug Administration - Published 2023-03-31 - Accessed 2026-09-19

    Scope: purpose, modality, anatomy, intendedUsers, input, output, limitations, evidenceSummary, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Butterfly iQ+ handheld ultrasound system

    Butterfly Network - Accessed 2026-09-03

    Scope: productFamily, workflowRole, integration, training, implementationCapabilities, currentCommercialContext

  8. Butterfly iQ+ specifications and security information

    Butterfly Network - Accessed 2026-09-03

    Scope: productFamily, integration, security, implementationCapabilities, currentCommercialContext

Research history

  1. K220068 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252074

Aplio i900, Aplio i800 and Aplio i700 Software V9.0 Diagnostic Ultrasound System

Canon Medical Systems Corporation

Authorized purpose: Aplio i900, i800, and i700 software V9.0 are mobile diagnostic ultrasound systems for multi-region imaging. K252074 adds deep-learning 3rd Harmonic Imaging for abdominal images; with specified endoscopic transducers, the Aplio i800/E3 also supports imaging of the upper gastrointestinal tract, surrounding organs, airways, tracheobronchial tree, and esophagus.

Modality
Ultrasound
Anatomy
Multi-region
Decision
2025-10-31
FDA-cleared K251963

LOGIQ E10s

Ge Medical Systems Ultrasound and Primary Care Diagnostics

Authorized purpose: LOGIQ E10s is a general-purpose diagnostic ultrasound system supporting the labeled adult, pediatric, cardiac, vascular, abdominal, obstetric, small-organ, musculoskeletal, urologic, and procedural applications.

Modality
Ultrasound
Anatomy
Multi-region
Decision
2025-10-29
FDA-cleared K251985

LOGIQ E10

Ge Medical Systems Ultrasound and Primary Care Diagnostics

Authorized purpose: LOGIQ E10 is a general diagnostic ultrasound system for qualified users across fetal and obstetric, abdominal, gynecologic, pediatric, small-organ, breast, cardiac, vascular, musculoskeletal, urologic, transrectal, transvaginal, transesophageal, and intraoperative applications.

Modality
Ultrasound
Anatomy
Multi-region
Decision
2025-10-29

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history